Epigral Eyes Rs 5,000 Cr Revenue by 2031

Specialty chemicals manufacturer Epigral is setting its sights on achieving Rs 5,000 crore in revenue by the fiscal year 2030-31. This strategic goal is largely driven by upcoming production scale-ups for CPVC Resin and Epichlorohydrin (ECH). The company projects its revenue to reach approximately Rs 2,900 crore in the current fiscal year, building on its Rs 2,500-2,530 crore revenue from 2026.

Capacity expansions for both CPVC Resin and ECH are imminent, with commissioning expected within the next couple of months. These expansions will begin to contribute to revenue partially this year, with a more significant impact anticipated from the next fiscal year. The company is doubling its CPVC Resin capacity from 75,000 TPA to 1,50,000 TPA and its ECH capacity from 50,000 TPA to 1,00,000 TPA at its Dahej, Gujarat facilities.

Epigral has established itself as a leader in import substitution, entering the ECH and CPVC resin markets in 2022. Notably, Epigral is the first Indian company to produce ECH using a 100% renewable glycerine-based process, distinguishing it from the Western crude-oil-based propylene route. With the capacity doubling, Epigral is poised to become the world's largest manufacturer of CPVC resin.

Looking ahead, Epigral has acquired new land in Dahej for a new chemistry line focused on import substitution at a larger scale. This new molecule is one where approximately 90% of India's current demand is met through imports. The company is in the process of finalizing a technology partner for this venture, with board approval expected within the next quarter. While specific capital expenditure details were not disclosed, it is estimated to exceed Rs 1,000 crore.